SCN9A and type 1 diabetes mellitus: Recently, it was reported that the pharmacological blockade of Nav1.7 reduced itching induced by methylglyoxal or in streptozotocin-induced diabetic mice, indicating that Nav1.7 played a key role in itching in a mouse model of type 1 diabetes [18].